GlassScriptPhysician profile
Nehal Ali Osman
NPI 1992352462
$6,245.25
in general payments reported to CMS, 2019-2025
27 companies · $19.44 in 2025
The $19.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $1,181 · 2023: $2,022 · 2024: $2,143 · 2025: $19.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.30 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,495.70 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,145.69 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $647.20 | 2021-2024 | |
| Novo Nordisk INC | $569.88 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $482.36 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $191.97 | 2021-2024 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $163.60 | 2021-2024 | Veozah |
| Sanofi Pasteur INC. | $157.62 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.81 | 2021-2024 | Jardiance |
| Mannkind Corporation | $140.30 | 2023 | V-Go, Afrezza |
| Sanofi-Aventis U.S. LLC | $136.45 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $131.28 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.64 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $122.19 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $104.61 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.15 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $77.85 | 2022 | |
| Exact Sciences Corporation | $59.29 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $54.83 | 2021 | |
| Esperion Therapeutics, INC. | $34.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.81 | 2021-2022 | |
| Amarin Pharma, INC. | $24.52 | 2021 | |
| Globus Medical, INC. | $19.44 | 2025 | Senza |
| Insulet Corporation | $18.74 | 2021 | |
| Evoke Pharma, INC. | $16.00 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.